Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214593387> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W4214593387 endingPage "5" @default.
- W4214593387 startingPage "1" @default.
- W4214593387 abstract "To investigate the clinical efficacy and safety of bevacizumab, apatinib, and recombinant human endothelial inhibitor in the treatment of advanced gastric cancer.The medical data of 204 patients with a medium to advanced gastric cancer assessed for eligibility treated in our hospital from February 2019 to April 2020 were retrospectively analyzed. The eligible patients were assigned at a ratio of 1 : 1:1 : 1 to either the control group (chemotherapy), study group I (bevacizumab combined with chemotherapy), study group II (apatinib combined with chemotherapy), or study group III (recombinant human endothelial inhibitor combined with chemotherapy) according to different treatment methods. The treatment efficacy, drug toxicity, quality of life, and serum tumor marker levels before and after treatment were compared among the four groups.Regarding the treatment effects, the effective rate of study group II (68.63%) was significantly higher than that of the control group (33.33%), study group I (58.82%), and study group III (49.02%) (P < 0.05). The four groups showed similar safety and tolerability profiles (P > 0.05). The treatment in study group II led to a significantly higher physiological function score vs. the other three groups, but the scores of other items were not significantly different. Significant reduction was observed in the serum tumor markers after treatment in the four groups (P < 0.05), but treatment in study group II led to a significantly greater reduction than the other three groups (P < 0.05).The addition of apatinib, bevacizumab, and recombinant human endothelial inhibitor injection to chemotherapy for the treatment of medium to advanced gastric cancer can significantly improve the clinical treatment efficacy, among which the use of apatinib combined with chemotherapy achieves the best results, which is worthy of clinical promotion." @default.
- W4214593387 created "2022-03-02" @default.
- W4214593387 creator A5000432967 @default.
- W4214593387 creator A5024013249 @default.
- W4214593387 creator A5025564615 @default.
- W4214593387 creator A5065402321 @default.
- W4214593387 creator A5070513635 @default.
- W4214593387 creator A5075733288 @default.
- W4214593387 date "2022-02-24" @default.
- W4214593387 modified "2023-09-26" @default.
- W4214593387 title "Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer" @default.
- W4214593387 cites W2581355973 @default.
- W4214593387 cites W2597613988 @default.
- W4214593387 cites W2735126203 @default.
- W4214593387 cites W2743927868 @default.
- W4214593387 cites W2755587235 @default.
- W4214593387 cites W2773474878 @default.
- W4214593387 cites W2775790492 @default.
- W4214593387 cites W2781914479 @default.
- W4214593387 cites W2783436536 @default.
- W4214593387 cites W2784317668 @default.
- W4214593387 cites W2788857340 @default.
- W4214593387 cites W2794016029 @default.
- W4214593387 cites W2802168390 @default.
- W4214593387 cites W2892113161 @default.
- W4214593387 cites W2946134515 @default.
- W4214593387 cites W2954903533 @default.
- W4214593387 cites W2993545757 @default.
- W4214593387 cites W3013347515 @default.
- W4214593387 cites W3046213609 @default.
- W4214593387 cites W3189746003 @default.
- W4214593387 cites W2618757357 @default.
- W4214593387 doi "https://doi.org/10.1155/2022/6189833" @default.
- W4214593387 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35251174" @default.
- W4214593387 hasPublicationYear "2022" @default.
- W4214593387 type Work @default.
- W4214593387 citedByCount "0" @default.
- W4214593387 crossrefType "journal-article" @default.
- W4214593387 hasAuthorship W4214593387A5000432967 @default.
- W4214593387 hasAuthorship W4214593387A5024013249 @default.
- W4214593387 hasAuthorship W4214593387A5025564615 @default.
- W4214593387 hasAuthorship W4214593387A5065402321 @default.
- W4214593387 hasAuthorship W4214593387A5070513635 @default.
- W4214593387 hasAuthorship W4214593387A5075733288 @default.
- W4214593387 hasBestOaLocation W42145933871 @default.
- W4214593387 hasConcept C121608353 @default.
- W4214593387 hasConcept C126322002 @default.
- W4214593387 hasConcept C143998085 @default.
- W4214593387 hasConcept C197934379 @default.
- W4214593387 hasConcept C2776694085 @default.
- W4214593387 hasConcept C2777802072 @default.
- W4214593387 hasConcept C2778375690 @default.
- W4214593387 hasConcept C2780668389 @default.
- W4214593387 hasConcept C535046627 @default.
- W4214593387 hasConcept C71924100 @default.
- W4214593387 hasConcept C90924648 @default.
- W4214593387 hasConceptScore W4214593387C121608353 @default.
- W4214593387 hasConceptScore W4214593387C126322002 @default.
- W4214593387 hasConceptScore W4214593387C143998085 @default.
- W4214593387 hasConceptScore W4214593387C197934379 @default.
- W4214593387 hasConceptScore W4214593387C2776694085 @default.
- W4214593387 hasConceptScore W4214593387C2777802072 @default.
- W4214593387 hasConceptScore W4214593387C2778375690 @default.
- W4214593387 hasConceptScore W4214593387C2780668389 @default.
- W4214593387 hasConceptScore W4214593387C535046627 @default.
- W4214593387 hasConceptScore W4214593387C71924100 @default.
- W4214593387 hasConceptScore W4214593387C90924648 @default.
- W4214593387 hasLocation W42145933871 @default.
- W4214593387 hasLocation W42145933872 @default.
- W4214593387 hasLocation W42145933873 @default.
- W4214593387 hasLocation W42145933874 @default.
- W4214593387 hasOpenAccess W4214593387 @default.
- W4214593387 hasPrimaryLocation W42145933871 @default.
- W4214593387 hasRelatedWork W2073582873 @default.
- W4214593387 hasRelatedWork W2087736549 @default.
- W4214593387 hasRelatedWork W2107697672 @default.
- W4214593387 hasRelatedWork W2110506075 @default.
- W4214593387 hasRelatedWork W2417717847 @default.
- W4214593387 hasRelatedWork W2546154929 @default.
- W4214593387 hasRelatedWork W2588654018 @default.
- W4214593387 hasRelatedWork W4221044984 @default.
- W4214593387 hasRelatedWork W4231596293 @default.
- W4214593387 hasRelatedWork W4380186280 @default.
- W4214593387 hasVolume "2022" @default.
- W4214593387 isParatext "false" @default.
- W4214593387 isRetracted "false" @default.
- W4214593387 workType "article" @default.